We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content. Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.
(The Center for Biosimilars) Apr 17, 2019 - Last year, the average rise of per employee cost of specialty drugs was 12%, with oncology making up the largest category.
(STAT Plus) Apr 18, 2019 - Citing lackluster financial performance, IBM is halting development and sales of a product that uses its Watson artificial intelligence software to help pharmaceutical companies discover new drugs, according to a person familiar with the company’s internal decision-making.
(University of Missouri) Apr 17, 2019 - Protein could be key to providing a precision medicine treatment to prevent the spread of cancer in people diagnosed with triple-negative breast cancer, MU study finds.
(STAT) Apr 18, 2019 - New advances won’t realize their full potential unless patients have access to them.
(Salk Institute) Apr 17, 2019 - Salk Institute researchers, along with an international team of collaborators, have uncovered the role of a signaling protein that may be the Achilles’ heel of pancreatic cancer.
(STAT) Apr 18, 2019 - On Thursday, the company is announcing an early breakthrough. Arrakis’ screening work has identified “hits” — oral drug-like compounds — that block the RNA machinery needed to make some well-known, cancer-causing proteins long thought to be beyond the reach of drug makers.
(Harvard Gazette) Apr 15, 2019 - Scientists from Harvard Medical School (HMS) have designed an algorithm that can successfully “read” the molecular signature of the cancer-driving defect and identify patients who could benefit from treatment with PARP inhibitors.
(Associated Press) Apr 18, 2019 - Vaxiion Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has concluded its 30-day review of the Investigational New Drug application (IND) for VAX014, and the company will now initiate a Phase 1 clinical trial for the treatment of non-muscle invasive bladder cancer (NMIBC).
(Imperial College London [UK]) Apr 17, 2019 - A simple blood test could help to detect breast cancer relapse up to two years earlier than imaging in patients with early-stage breast cancer.
(STAT Plus) Apr 17, 2019 - Shares of Turning Point Therapeutics, a San Diego-based developer of targeted cancer drugs, soared 57% following the company’s initial public offering on Wednesday.